Navigation Links
Second-line CML drug evokes faster response, fewer side effects, pivotal study finds
Date:6/5/2010

CHICAGO - Dasatanib, a medication currently approved as treatment for drug-resistant chronic myeloid leukemia (CML), provided patients with quicker, better responses as a first therapy than the existing front-line drug, according to researchers at The University of Texas MD Anderson Cancer Center.

The findings were presented at the 46th Annual Meeting of the American Society of Clinical Oncology today, and published in the New England Journal of Medicine. Hagop Kantarjian, M.D., professor and chair of MD Anderson's Department of Leukemia, presented the findings and is the corresponding author on the published study.

Currently, imatinib, or Gleevec , is the approved initial therapy for CML, which has increased the five-year survival rate for the disease from 50 percent to 90 percent, said Kantarjian. However, 30-40 percent of imatinib patients do not achieve confirmed cytogenic complete response (CCyR), or the absence of the defective chromosome that causes the disease, within a year. This benchmark is clearly associated with improvements in long-term outcome, said Kantarjian.

"Previous research conducted at MD Anderson found that more patients taking dasatinib were achieving complete responses more quickly than they do on the current standard of care," said Kantarjian. "In this pivotal Phase III study, we confirmed that dasatinib gets more patients to high-quality remission faster than imatinib, making it a superior front-line therapy. Dasatinib, on average, also has a more favorable side-effect profile."

For the multinational Phase III study, known as DASSIN (Dasatinib versus Imatinib Study In treatment-nave CML patients), 519 newly diagnosed CML patients who had received no prior treatment were randomized to receive either dasatinib, also known as Sprycel , 100 milligrams once daily (259 patients), or imatinib, 400 milligrams once daily (260 patients). CCyR, confirmed on two assessments, was the study's primary endpoint. Secondary endpoints included rate of and times to CCyR and major molecular response (MMR), defined as a level of .1 percent or lower of the defective chromosome, as well as safety.

After a minimum follow-up of 12 months, the researchers found that the rates of confirmed CCyR and MMR in those taking dasatinib were 77 percent and 46 percent, respectively, compared to 66 percent and 28 percent, on the imatinib arm.

Therapy failed in nine patients (3.5 percent) in those taking imatinib, compared to five patients (1.9 percent) taking dasatanib. The dasatanib arm reported fewer side effects - nausea, vomiting, muscle inflammation, rash, fluid retention - with most other toxicities being similar in both arms.

"We've learned that in cancer therapy, it's important to use your big guns up front. We know that achieving complete cytogenetic response within a year of starting treatment is associated with more favorable long-term survival; therefore, using this second-generation drug first will likely improve outcomes for patients with chronic myeloid leukemia," said Kantarjian.

CML is caused by an abnormality known as the Philadelphia chromosome that produces an aberrant protein, Bcr-Abl, which causes the overproduction of one type of white blood cell that drives the disease. Dasatinib, a tyrosine kinase inhibitor, blocks the action of Bcr-Abl; the drug is currently approved by the U.S. Food and Drug Administration for patients who can't tolerate imatinib or whose CML resists the drug.


'/>"/>

Contact: Laura Sussman
lsussman@mdanderson.org
832-264-8893
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. Second-line CML drugs evoke faster response than front-line therapy
2. Patient age not a factor in use of second-line therapy for lung cancer
3. Cost of Psoriasis Drugs Rising Faster Than Others
4. Faster Heart Rate May Raise Risk of Heart Attack Death
5. Blacks with MS have more severe symptoms, decline faster than whites, new study shows
6. Second Language Comes Faster When Taught in Own Accent
7. 'Get Pregnant' Aims To Help Couples Conceive Naturally, Faster
8. Minimally invasive sports hernia repair may get athletes back in the game faster, study says
9. SAN SnapShot Backup for VMWare - Does Your Backup Always Completes In Seconds, Is 1000x Faster and Costs 90% Less?
10. Cognition declines 4 times faster in people with Alzheimers disease than those with no dementia
11. Alterian Releases Professional Edition of its Content Manager Technology, Offering Partners and Clients an Even Faster Time-to-Live for Their Websites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... Recognising that in today’s busy world consumers are often ... in just three weeks. Setting the groundwork for a healthier lifestyle, Leany Greeny ... work and family schedules, participants can lose up to 15lbs during the program ...
(Date:9/20/2017)... ... September 20, 2017 , ... Houston, Texas, investment firm CORDA Investment Management, ... and Monday, September 11, off work and rolled up their sleeves to help with ... local homes to start the process of rebuilding. , CORDA founder Bonner C. Barnes ...
(Date:9/20/2017)... ... ... “The Financial Favor of God; Second Edition”: a personal and exquisite recipe for financial ... published author, Brooks Rathell. , “We typically hear about the favor of God. I ... of God. Not only does it exist, but it is meant for you. I ...
(Date:9/19/2017)... ... 2017 , ... Only a few physicians were selected to receive the prestigious ... Clevens, MD, FACS . The founder and medical director of Clevens Face and ... at Yale, Harvard and the University of Michigan. He has served patients throughout Central ...
(Date:9/19/2017)... ... 19, 2017 , ... Peter Chandonait, Abt Associates Principal Scientist ... (PMI) Africa Indoor Residual Spraying (AIRS) Project , has been named the Grand ... Action Award, a USAID Catalyst Award, recognizes USAID staff and implementing partners who ...
Breaking Medicine News(10 mins):
(Date:8/29/2017)... RANDOLPH, N.J. , Aug. 29, 2017 ... inventory management, security, and regulatory compliance for veterinary practices ... today announced a new partnership that makes TITAN,s expertise ... legal compliance available to Cubex,s clients nationally. ... healthcare provider buying and handling controlled substances is at ...
(Date:8/28/2017)... division of LightScalpel ®, LLC, is announcing its new line of ... American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary laser surgery once ... ... VetScalpel laser. Dr. Duclos practices veterinary dermatology at the Animal Skin and ... ...
(Date:8/25/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a global ... management will be presenting a West business overview at three ... Management will present at the Baird 2017 Global Healthcare Conference, ... York, N.Y. , at 3:10 p.m. EDT on Wednesday, ... Westin Boston Waterfront in Boston, Mass. , ...
Breaking Medicine Technology: